中樞神經的藥物開發：未來動向

中樞神經的藥物開發：未來動向 是由出版商Espicom Business Intelligence在2008年08月所出版的。 這份英文市場調查報告書包含Pages: 446 價格從美金3140起跳。

簡介

本報告書內容包括:多發性硬化症、帕金森氏症、阿茲海默症、精神分裂症、憂鬱症的五個中樞神經系統疾病治療為焦點、2014年為止的產品市場佔有率和銷售額預測、今後上市預定的產品概要等、內容綱要摘記如下:

實施摘要

阿茲海默症

• 現況
  • 患者統計
  • 患者模式
  • 成長因素
  • 風險和阻礙因素
• 市場
• 目前的治療法
• 研究開發的新藥品
• 競爭分析
  • 產品
  • 企業
  • 勝者和敗者
• 藥劑開發中止
• 附錄

多發性硬化症

• 現況
  • 患者統計
  • 患者模式
  • 成長要素
  • 風險和阻礙因素
• 市場
• 目前的治療法
• 研究開發的新藥品
• 競爭分析
  • 產品
  • 企業
  • 勝者和敗者
• 藥劑開發中止
• 附錄

憂鬱症

• 現況
  • 患者統計
  • 患者模式
  • 成長要素
  • 風險和阻礙因素
• 市場
• 目前的治療法
• 研究開發的新藥品
• 競爭分析
  • 產品
  • 企業
  • 勝者和敗者
• 藥劑開發中止
• 附錄

帕金森氏症

• 現況
  • 患者統計
  • 患者模式
  • 成長要素
  • 風險和阻礙因素
• 市場
• 目前的治療法
• 研究開發的新藥品
• 競爭分析
  • 產品
  • 企業
  • 勝者和敗者
• 藥劑開發中止
• 附錄

精神分裂症

• 現況
  • 患者統計
  • 患者模式
  • 成長要素
  • 風險和阻礙因素
• 市場
• 目前的治療法
• 研究開發的新藥品
• 競爭分析
  • 產品
  • 企業
  • 勝者和敗者
• 藥劑開發中止
• 附錄

目錄

Abstract

A comprehensive examination of 5 CNS therapy areas: multiple sclerosis, Parkinson' s disease, Alzheimer' s disease, schizophrenia and depression. The report includes unique market share and sales forecasts by product to 2014, as well as detailed competitor analysis of current and upcoming products.

Features:

• Unique market share and sales forecasts by product to 2014
• A comprehensive examination of 5 major CNS therapy areas
• Detailed competitor analysis of current and upcoming products

• Five key CNS sectors
  • Alzheimer' s disease
  • Multiple sclerosis
  • Depression
  • Parkinson' s disease
  • Schizophrenia

• With this new 400+ page analysis you can...
  • Easily evaluate and understand the prospects for 60 leading and upcoming products
  • Assess the impact on companies of new product introduction
  • Understand the impact of generic competition in key sectors
  • Appreciate the drivers and dampeners which will help or hinder market growth
  • Review the Phase II product pipeline

Table of Contents

EXECUTIVE SUMMARY

• Global CNS Market 2007 (US$91.9 billion)
• Competitor Ratio Analysis Summary
• Competitor Ratio Analysis - Drugs
  • CNS Drugs Analysed for Launch by 2014 - Therapeutic Category
• Competitor Ratio Analysis - Companies
  • CNS Drugs Analysed for Launch by 2014 - by Company
  • Pharmaceutical Companies and Products Analysed in this Report
  • Key:

ALZHEIMER' S DISEASE

• EXECUTIVE SUMMARY
• THE FACTS
  • What is Alzheimer' s disease and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • The treatable AD patient population will grow by 2.7 per cent per annum
    • Summary of AD Patient Population Forecasts 2007A-2014E
  • Model Assumptions
• DRUG GROWTH DRIVERS
  • Potential Diagnostic Biomarkers for AD
• DRUG GROWTH RISKS/DAMPENERS

THE AD MARKET

• Global CNS Market (US$91.9 billion)
• AD Global Sales Split (2006)
• THE MAJOR PLAYERS
  • Market Share of AD Players by Sales (Dec 2007A)
• PLAYERS AND PRODUCTS IN 2014
  • Market Share of AD Players by Sales (Dec 2014E)

CURRENT AD TREATMENTS

• Leading Brands
  • Comparison of Leading AD Drugs
• Current Products' Patent Exposure
  • Patent Exposure of Leading AD Brands

ANALYSIS OF LEADING BRANDS

• Acetylcholinesterase (AChE) Inhibitors
  • Aricept
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approvals
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Exelon
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Razadyne
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• NMDA Antagonist
  • Namenda/Ebixa
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E
  • Sales Forecasts of Current Leading AD Drugs
• Model Assumptions

NEW DRUGS IN R&D

• Drugs in Development to Treat AD
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat AD
  • Bapineuzumab
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Flurizan
    • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor ratio analysis
• LY450139

GLOBAL SALES FORECASTS OF PHASE III AD DRUGS 20011E - 2014E

• Sales Forecasts of Phase III Developmental AD Drugs
• Model Assumptions

ANALYSIS OF PHASE II DRUGS

• Drugs in Phase II Development to Treat AD
  • CX717
  • EVT 101
  • Ketasyn
  • MEM 1003
  • MEM 3454
  • PBT2

COMPETITOR RATIO ANALYSIS

• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • CR Analysis of AD Agents Approved by 2014 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of AD and PD Agents Approved by 2014 - Based on Company
• WINNERS & LOSERS
  • Summary of Key Companies and Drugs in the AD Market by 2014

DISCONTINUATION OF DRUGS

• AD Drugs Discontinued from Clinical Development

AD APPENDIX 1

• Phase Transition Probability
  • Probability of Launch

AD APPENDIX 2

• AD Patient Model
  • Summary of AD Patient Population Forecasts

AD APPENDIX 3

• Global AD Drugs Sales 2007A-2014E
  • Global AD Drug Sales 2007A-2014E

AD APPENDIX 4

• Competitor Ratio Analysis Criteria
  • Key AD Drugs on the Market by 2014

ALZHEIMER' S DISEASE GLOSSARY

ALZHEIMER' S DISEASE REFERENCES

ACRONYMS

MULTIPLE SCLEROSIS

• EXECUTIVE SUMMARY

THE FACTS

• What is multiple sclerosis and why are we interested in it?
• PATIENT STATISTICS
• Incidence, diagnosis rates and treatment; now and in the future
• MS Categories
  • Types of MS
• PATIENT MODEL
  • The treatable MS patient population will have a CAGR 2007E-2014E - 2.5 per cent
    • Summary of Patient Population Forecasts (2007A-2014E)
  • Model Assumptions
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

THE MS MARKET

• Global CNS Market (US$91.9 billion)
• The Major Players
  • Market Share of Major MS Players by Sales (Dec 2007A)
• Players and Products in 2007
• Players and Products in 2014

CURRENT MS TREATMENTS

• Leading Brands
  • Comparison of Leading MS Agents
• Current Products' Patent Exposure
  • Patent Exposure of Leading MS Brands

ANALYSIS OF LEADING BRANDS

• Disease-modifying Agents
  • Avonex
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Betaferon/Betaseron
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Copaxone
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Rebif
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Competitor ratio analysis
  • Tysabri
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Novantrone
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis

GLOBAL SALES FORECASTS OF CURRENT TREATMENTS

• Sales Forecasts of Current Leading MS Drugs
• Model Assumptions

NEW DRUGS IN R&D

• Drugs in Development to Treat MS

ANALYSIS OF PHASE III DRUGS

• New Drugs in Phase III Development to Treat MS
• Disease-modifying Agents
  • BG-12
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Campath
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Fingolimod
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Laquinimod
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • MBP8298
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Mylinax
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Teriflunomide
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• MS Symptoms
  • Neurelan
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
  • Trial MS-F202: Timed 25-foot Walk Response Rate of MS Patients Treated with
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis

GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2009E-

• Sales Forecasts of Phase III Developmental MS Drugs
• Model Assumptions

ANALYSIS OF PHASE II DRUGS

• New Drugs in Early Clinical Development to Treat MS
• Disease-modifying Agents
  • ATL1102/TV1102
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • CDP323
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Daclizumab
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Firategrast
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Ibudilast
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Vaccines
  • BHT-3009
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecast and assumptions
    • Competitor ratio analysis
  • NeuroVax
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Tovaxin
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis

GLOBAL SALES FORECASTS OF PHASE II MS DRUGS

• Sales Forecasts of Phase II Developmental MS Drugs
• Model Assumptions

COMPETITOR RATIO ANALYSIS

• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • CR Analysis of MS Agents Approved by 2014 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of MS Agents Approved by 2014 - Based on Company
• WINNERS & LOSERS
  • Summary of Key Companies and Drugs in the MS Market by 2014

DISCONTINUATION OF DRUGS

• MS Drugs Discontinued from Clinical Development

MS APPENDIX 1

• Clinical Diagnostic Test for MS

MS APPENDIX 2

• Expanded Disability Status Scale (EDSS)

MS APPENDIX 3

• Phase Transition Probability
  • Probability of Launch

MS APPENDIX 4

• MS Patient Model
  • Summary of US MS Patient Population Forecasts
  • Summary of Europe (Top 5) MS Patient Population Forecasts
  • Summary of Japan MS Patient Population Forecasts

MS APPENDIX 5

• Global MS Drugs Sales 2007A-2014E
  • Global MS Drug Sales 2007A-2014E

MS APPENDIX 6

• Competitor Ratio Analysis Criteria
  • Key MS Drugs on the Market by 2014

MS GLOSSARY

MS REFERENCES

ACRONYMNS

DEPRESSION

• EXECUTIVE SUMMARY

THE FACTS

• What is depression and why are we interested in it?
• PATIENT STATISTICS
• Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • Summary of Depression Patient Population Forecasts in Seven Major Markets (2007E-2014E)
• Model Assumptions
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

THE ANTIDEPRESSANT MARKET

• Global CNS Market 2007 (US$919 billion)
• Global Sales Split by Drug Class (2007A)
• Global Sales Split by Region (2006)
• The Major Players Products in 2007
  • Market Share of Antidepressant Players by Sales (Dec 2007A)
• The Major Players and Products in 2014
  • Market Share of Antidepressant Players by Sales (Dec 2014E)

CURRENT TREATMENTS

• Leading Brands
  • Comparison of Leading Antidepressant Drugs
• Current Products' Patent Exposure
  • Patent Exposure of Leading Antidepressant Brands

ANALYSIS OF LEADING BRANDS

• Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Lexapro/Cipralex
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Prozac
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Seroxat/Paxil
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Zoloft
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
  • Cymbalta
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Effexor
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Pristiq
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Noradrenaline and Dopamine Reuptake Inhibitors (NDRIs)
  • Wellbutrin
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E
  • Sales Forecasts of Current Leading Antidepressant Drugs
• Model Assumptions

NEW DRUGS IN R&D

• Drugs in Development to Treat Depression and Anxiety Related Disorders

ANALYSIS OF PHASE III DRUGS

• New Drugs in Phase III Development to Treat Depression and Anxiety
• Neurokinin Receptor Antagonist
  • Saredutant
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Melatonergic Receptor Agonist
  • Valdoxan
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical experience
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Other Late-Phase Drugs
  • Amibegron
  • Seroquel
  • Vilazodone

GLOBAL SALES FORECASTS OF PHASE III ANTIDEPRESSANT AND ANTI-ANXIETY DRUGS 2009E - 2014E

• Sales Forecasts of Phase III Developmental Drugs for Depression and Anxiety
• Model Assumptions

ANALYSIS OF PHASE II DRUGS

• New Drugs in Early Clinical Development to Treat Depression and Anxiety
• Triple Uptake Inhibitor
  • NS2359
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Other Phase II Drugs of Interest
  • DOV 21,947
  • MN-305

GLOBAL SALES FORECASTS OF PHASE II ANTIDEPRESSANT DRUGS 2010E - 2014E

• Sales Forecasts of Phase II Developmental Antidepressant Drugs
• Model Assumptions

COMPETITOR RATIO ANALYSIS

• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • CR Analysis of Antidepressant Agents Approved by 2014 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of Antidepressant Agents Approved by 2014 - Based on Company
• WINNERS & LOSERS
  • Summary of Key Companies and Drugs in the Antidepressant Market by 2014
• Winners
• Losers

DISCONTINUATION OF DRUGS

• Antidepressants/Anxiolytics Discontinued from Clinical Development

DEPRESSION APPENDIX 1

• Assessment of Depression Criteria

DEPRESSION APPENDIX 2

• Phase Transition Probability
  • Probability of Launch

DEPRESSION APPENDIX 3

• Patient Model
  • Summary of US Depression and Anxiety Patient Population Forecasts
  • Summary of Europe (Top 5) Depression and Anxiety Patient Population Forecasts
  • Summary of Japanese Depression and Anxiety Patient Population Forecasts

DEPRESSION APPENDIX 4

• Global Antidepressant Drugs Sales 2007A-20014E

DEPRESSION APPENDIX 5

• Competitor Ratio Analysis Criteria
  • Key Antidepressant/Anxiolytic Drugs on the Market by 2014

DEPRESSION GLOSSARY

DEPRESSION REFERENCES

ACRONYMS

Parkinson ' s Disease

• EXECUTIVE SUMMARY

THE FACTS

• What is Parkinson' s disease and why are we interested in it?
• PATIENT STATISTICS
• Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
• The treated PD patient population will grow by 36 per cent per annum
  • Summary of PD Patient Population Forecasts 2007A-2014E
• Model Assumptions
• DRUG GROWTH DRIVERS
  • Potential Diagnostic Biomarkers for PD
• DRUG GROWTH RISKS/DAMPENERS

THE PD MARKET

• Global CNS Market 2007 (US$919 billion)
• PD Global Sales Split (2006)
• The Major Players
  • Market Share of PD Players by Sales (Dec 2007A)
• Players and Products in 2014
  • Market Share of PD Players by Sales (Dec 2014E)

CURRENT PD TREATMENTS

• Leading Brands
  • Comparison of Leading PD Drug Classes
• Current Products' Patent Exposure
  • Patent Exposure of Leading PD Brands

ANALYSIS OF LEADING BRANDS

• Dopamine Agonists
  • Apokyn
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Neupro
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Clinical Endpoint of Phase III trials with Neupro 1) Europe 2) the US
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Sifrol/Mirapex/Mirapexin
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Requip
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Monoamine Oxidase Inhibitors
  • Azilect
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Catechol-O-Methyltransferase Inhibitors
  • Comtan/Comtess/Stalevo
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E
  • Sales Forecasts of Current Leading PD Drugs
• Model Assumptions

NEW DRUGS IN R&D

• Drugs in Development to Treat PD
• ANALYSIS OF LATE-PHASE DRUGS
  • New Drugs in Phase III Development to Treat PD
  • Istradefylline
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Pardoprunox
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Safinamide
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• GLOBAL SALES FORECASTS OF LATE-PHASE PD DRUGS 2009E - 2014E
  • Sales Forecasts of Late-Phase Developmental PD Drugs
• Model Assumptions

ANALYSIS OF PHASE II DRUGS

• New Drugs in Early Clinical Development to Treat PD
  • Spheramine
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• VR040

COMPETITOR RATIO ANALYSIS

• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • CR Analysis of PD Agents Approved by 2014 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of PD Agents Approved by 2014 - Based on Company
• WINNERS & LOSERS
  • Summary of Key Companies and Drugs in the PD Market by 2014

DISCONTINUATION OF DRUGS

• PD Drugs Discontinued from Clinical Development

PD APPENDIX 1

• Phase Transition Probability
  • Probability of Launch

PD APPENDIX 2

• PD Patient Model
  • Summary of PD Patient Population Forecasts

PD APPENDIX 3

• Global PD Drugs Sales 2007A-2014E
  • Global PD Drug Sales 2007A-2014E

PD APPENDIX 4

• Competitor Ratio Analysis Criteria
  • Key PD Drugs on the Market by 2014

PARKINSON' S DISEASE GLOSSARY

PARKINSON' S DISEASE REFERENCES

ACRONYMS

SCHIZOPHRENIA

• EXECUTIVE SUMMARY

THE FACTS

• What is schizophrenia and why are we interested in it?
  • Symptoms Associated with Schizophrenia
  • Schematic Depicting Mood Swings in Bipolar Disorder
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • Summary of Patient Population Forecasts 2007A-2014E
• Model Assumptions
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

THE SCHIZOPHRENIA MARKET

• Global CNS Market 2007 (US$919 billion)
• Global Sales Split (2006)
• The Major Players
  • Market Share of Antipsychotic Players by Sales (Dec 2007A)
• Players and Products in 2007
• Players and Products in 2014
  • Market Share of Antipsychotic Players by Sales (Dec 2014E)

CURRENT TREATMENTS

• Leading Brands
  • Comparison of Leading Antipsychotic Drugs
• Current Products' Patent Exposure
  • Patent Exposure of Leading Antipsychotic Brands
• ANALYSIS OF LEADING BRANDS
• Atypical Antipsychotics
  • Abilify
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Geodon/Zeldox
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Invega
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Lonasen
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Clinical Efficacy of Blonanserin
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Risperdal
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Seroquel
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Zyprexa
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• Other Atypical Antipsychotics
  • Serdolect
  • Lullan
  • Clozaril/Leponex
  • Solian

GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E

• Sales Forecasts of Current Leading Antipsychotics
• Model Assumptions

NEW DRUGS IN R&D

• Drugs in Development to Treat Schizophrenia and Bipolar Disorder
• ANALYSIS OF LATE-PHASE DRUGS
  • Drugs in Late-Phase Development to Treat Schizophrenia and Bipolar Disorder
• D/5-HT Receptor Antagonists
  • Asenapine
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Bifeprunox
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Lurasidone
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Fanapta
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the market-place/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Safety Profile of Iloperidone vs Approved Antipsychotics
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis

GLOBAL SALES FORECASTS OF LATE-PHASE SCHIZOPHRENIA DRUGS 2008E - 2014E

• Sales Forecasts of Late-Phase Developmental Antipsychotic Drugs
• Model Assumptions

ANALYSIS OF PHASE II DRUGS

• BL-1020
• Cariprazine
• EVP-6124
• MEM 3454
• LY2140023
• Vabicaserin

COMPETITOR RATIO ANALYSIS

• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • CR Analysis of Antipsychotic Agents Approved by 2014 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of Antipsychotics Approved by 2014 - Based on Company
• WINNERS & LOSERS
  • Summary of Key Companies and Drugs in the Antipsychotic Market by 2014
• Winners
• Losers

DISCONTINUATION OF DRUGS

• Antipsychotic Drugs Discontinued from Clinical Development

SCHIZOPHRENIA APPENDIX 1

• ASSESSMENT OF ANTIPSYCHOTIC EFFICACY IN SCHIZOPHRENIA
• ASSESSMENT OF ANTIPSYCHOTIC EFFICACY IN BIPOLAR DISORDER

SCHIZOPHRENIA APPENDIX 2

• Phase Transition Probability
  • Probability of Launch

SCHIZOPHRENIA APPENDIX 3

• Patient Model
  • Summary of US Schizophrenia Patient Population Forecasts
  • Summary of European (Top 5) Schizophrenia Patient Population Forecasts
  • Summary of Japanese Schizophrenia Patient Population Forecasts

SCHIZOPHRENIA APPENDIX 4

• Global Antipsychotic Drug Sales 2007A-2014E

SCHIZOPHRENIA APPENDIX 5

• Competitor Ratio Analysis Criteria
  • Key Antipsychotic Drugs on the Market by 2014

SCHIZOPHRENIA GLOSSARY

SCHIZOPHRENIA REFERENCES

• ACRONYMS

相關商品